|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS: | ||||||||||||||||||||
| Mortgage-backed securities, at fair value (includes pledged assets of $10,613,780 and $10,502,743, respectively) | ||||||||||||||||||||
| Pledged assets | ||||||||||||||||||||
| U.S. Treasury securities, available-for-sale (amortized cost of $125,154 and $100,412; includes pledged assets of $120,581 and $100,551, respectively) | ||||||||||||||||||||
| U.S. Treasury securities, available-for-sale (amortized cost of $208,279 and $134,715; includes pledged assets of $207,861 and $135,133, respectively) | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Accrued interest receivable | ||||||||||||||||||||
| Derivative assets | ||||||||||||||||||||
| Receivable for unsettled TBA transactions | ||||||||||||||||||||
| Reverse repurchase agreements | ||||||||||||||||||||
| Receivable for investment securities and TBA transactions | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| LIABILITIES: | ||||||||||||||||||||
| Repurchase agreements | ||||||||||||||||||||
| Payable for unsettled TBA transactions | ||||||||||||||||||||
| Payable for investment securities and TBA transactions | ||||||||||||||||||||
| Dividends payable | ||||||||||||||||||||
| Derivative liabilities | ||||||||||||||||||||
| Accrued interest payable | ||||||||||||||||||||
| Due to affiliates | ||||||||||||||||||||
| Obligation to return securities borrowed under reverse repurchase agreements, at fair value | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| STOCKHOLDERS' EQUITY: | ||||||||||||||||||||
| Preferred stock, $0.01 par value; 20,000,000 shares authorized; no shares issued and outstanding as of September 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Common Stock, $0.01 par value; 400,000,000 shares authorized, 194,661,864 shares issued and outstanding as of September 30, 2026 and 181,985,900 shares issued and outstanding as of December 31, 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive (loss) income | ||||||||||||||||||||
| Total Stockholders' Equity | ||||||||||||||||||||
| Total Liabilities and Stockholders' Equity | ||||||||||||||||||||
Loading...
